CTLA4 and neoplasm: ICIs trigger an anti-tumor immune response by targeting inhibitory pathways in T-cells, including Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), Programmed Cell Death Protein-1 (PD-1), and its ligand PD-L1.